Orphan drugs to treat myasthenia gravis

Research output: Contribution to journalArticle

Abstract

Introduction: Acquired myasthenia gravis (MG) is a rare disease and according to the EU Register of designated Orphan Medicinal Products only two drugs are registered as orphan drugs for MG while no orphan drug for MG has been approved by the US Food and Drug Administration. The aim of this review is to discuss the role and mechanism of action of the recognized orphan drugs for MG and of other therapies potentially useful for MG treatment, which should be considered as orphan drugs. Areas covered: In the context of an updated overview of MG pathogenesis, the authors discuss current MG treatments available in clinical practice, orphan drugs for MG according to the EU Orphan Drugs Registry and emerging therapies, among which are therapies exclusively developed for MG. Expert opinion: New effective drugs for MG are needed to reduce side effects, mainly those related to steroids or to chronic immunosuppression, and to manage patients not responsive to common treatments. Hence, in recent years drugs potentially targeting selective pathogenetic steps of MG have been developed, although the complexity of the immune system makes their application very challenging. To this purpose a great effort at multiple levels, including basic research, clinical practice and health politics, will be necessary.

Original languageEnglish
Pages (from-to)373-384
Number of pages12
JournalExpert Opinion on Orphan Drugs
Volume1
Issue number5
DOIs
Publication statusPublished - 2013

Fingerprint

Orphan Drug Production
Myasthenia Gravis
Therapeutics
Orphaned Children
Expert Testimony
United States Food and Drug Administration
Politics
Drug Delivery Systems
Rare Diseases
Pharmaceutical Preparations
Immunosuppression
Registries
Immune System

Keywords

  • Cellular therapies
  • Emerging therapies
  • Monoclonal antibodies
  • Myasthenia gravis
  • Orphan drugs
  • Treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Orphan drugs to treat myasthenia gravis. / Maggi, Lorenzo; Baggi, Fulvio; Mantegazza, Renato.

In: Expert Opinion on Orphan Drugs, Vol. 1, No. 5, 2013, p. 373-384.

Research output: Contribution to journalArticle

@article{349191955cf3422a89ababe1728254f6,
title = "Orphan drugs to treat myasthenia gravis",
abstract = "Introduction: Acquired myasthenia gravis (MG) is a rare disease and according to the EU Register of designated Orphan Medicinal Products only two drugs are registered as orphan drugs for MG while no orphan drug for MG has been approved by the US Food and Drug Administration. The aim of this review is to discuss the role and mechanism of action of the recognized orphan drugs for MG and of other therapies potentially useful for MG treatment, which should be considered as orphan drugs. Areas covered: In the context of an updated overview of MG pathogenesis, the authors discuss current MG treatments available in clinical practice, orphan drugs for MG according to the EU Orphan Drugs Registry and emerging therapies, among which are therapies exclusively developed for MG. Expert opinion: New effective drugs for MG are needed to reduce side effects, mainly those related to steroids or to chronic immunosuppression, and to manage patients not responsive to common treatments. Hence, in recent years drugs potentially targeting selective pathogenetic steps of MG have been developed, although the complexity of the immune system makes their application very challenging. To this purpose a great effort at multiple levels, including basic research, clinical practice and health politics, will be necessary.",
keywords = "Cellular therapies, Emerging therapies, Monoclonal antibodies, Myasthenia gravis, Orphan drugs, Treatment",
author = "Lorenzo Maggi and Fulvio Baggi and Renato Mantegazza",
year = "2013",
doi = "10.1517/21678707.2013.779920",
language = "English",
volume = "1",
pages = "373--384",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Orphan drugs to treat myasthenia gravis

AU - Maggi, Lorenzo

AU - Baggi, Fulvio

AU - Mantegazza, Renato

PY - 2013

Y1 - 2013

N2 - Introduction: Acquired myasthenia gravis (MG) is a rare disease and according to the EU Register of designated Orphan Medicinal Products only two drugs are registered as orphan drugs for MG while no orphan drug for MG has been approved by the US Food and Drug Administration. The aim of this review is to discuss the role and mechanism of action of the recognized orphan drugs for MG and of other therapies potentially useful for MG treatment, which should be considered as orphan drugs. Areas covered: In the context of an updated overview of MG pathogenesis, the authors discuss current MG treatments available in clinical practice, orphan drugs for MG according to the EU Orphan Drugs Registry and emerging therapies, among which are therapies exclusively developed for MG. Expert opinion: New effective drugs for MG are needed to reduce side effects, mainly those related to steroids or to chronic immunosuppression, and to manage patients not responsive to common treatments. Hence, in recent years drugs potentially targeting selective pathogenetic steps of MG have been developed, although the complexity of the immune system makes their application very challenging. To this purpose a great effort at multiple levels, including basic research, clinical practice and health politics, will be necessary.

AB - Introduction: Acquired myasthenia gravis (MG) is a rare disease and according to the EU Register of designated Orphan Medicinal Products only two drugs are registered as orphan drugs for MG while no orphan drug for MG has been approved by the US Food and Drug Administration. The aim of this review is to discuss the role and mechanism of action of the recognized orphan drugs for MG and of other therapies potentially useful for MG treatment, which should be considered as orphan drugs. Areas covered: In the context of an updated overview of MG pathogenesis, the authors discuss current MG treatments available in clinical practice, orphan drugs for MG according to the EU Orphan Drugs Registry and emerging therapies, among which are therapies exclusively developed for MG. Expert opinion: New effective drugs for MG are needed to reduce side effects, mainly those related to steroids or to chronic immunosuppression, and to manage patients not responsive to common treatments. Hence, in recent years drugs potentially targeting selective pathogenetic steps of MG have been developed, although the complexity of the immune system makes their application very challenging. To this purpose a great effort at multiple levels, including basic research, clinical practice and health politics, will be necessary.

KW - Cellular therapies

KW - Emerging therapies

KW - Monoclonal antibodies

KW - Myasthenia gravis

KW - Orphan drugs

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84896736212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896736212&partnerID=8YFLogxK

U2 - 10.1517/21678707.2013.779920

DO - 10.1517/21678707.2013.779920

M3 - Article

AN - SCOPUS:84896736212

VL - 1

SP - 373

EP - 384

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 5

ER -